OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Company News Release
WILMINGTON, N.C., Jan. 13 /PRNewswire/-Inclinix, Inc., a clinical trial enrollment solutions provider, announces the release of its next generation Critical Population Research(R) (CPR) system. A proprietary technology that integrates numerous public and private databases, CPR analyzes each investigator site for multiple criteria to identify the optimal sites for clinical trials. The CPR database has been expanded to include profiles on 40,000 additional investigators, now totaling over 100,000, including thousands of international investigators. This international capacity provides sponsors with a global analysis of prospective sites.
Critical Population Research identifies where patients with a specific condition are concentrated by providing color-coded maps of disease prevalence from national to ZIP code level. These maps identify clusters of sites that maximize media budgets and even provide visual insight into geographic barriers to clinical trial participation, such as availability of public transportation or parking. Inclinix's Media Optimizer uses this aspect of CPR as its foundation, implementing only the most effective and cost-efficient patient outreach for each site. This process, complemented by the extensive CPR investigator database, provides a powerful dataset for site selection and patient recruitment.
"The clinical trials industry has repeatedly identified site initiation as a primary cause of delays," explains J. Tobin Geatz, Inclinix President and CEO. "Our enhanced CPR technology offers our clients a proven, scientific solution to investigator site selection. By initiating only the most qualified investigators who have access to the right patients, trials will enroll - and ultimately complete - faster and at less cost."
In a three-year retrospective analysis of multiple trials, Inclinix found that investigators located in CPR "hot zones" (areas of high disease prevalence) enrolled at a rate nearly three times faster than those located in "cold zones" (areas of low disease prevalence). This data-driven approach to site selection results in identification of the most qualified investigators, leading to faster, more effective patient recruitment and trial completion.
Inclinix, Inc. specializes in customized Phase I-IV clinical trial enrollment solutions that deliver productive investigator sites and qualified patients for the pharmaceutical, biotech and medical device industry. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance. For more information, visit www.inclinix.com